Myllia Biotechnology is a cutting-edge brand at the forefront of genetic screening and drug target identification. Utilizing the revolutionary CROP-Seq (CRISPR Droplet Sequencing) workflow developed by our co-founder Christoph Bock, we can map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution. This groundbreaking technology enables us to conduct next generation CRISPR screens, with broad applications in identifying novel drug targets, unraveling unknown mechanisms of drug actions, and understanding genetic variants linked to disease risk.

Our end-to-end platform for tailor-made CRISPR screens sets us apart, as we routinely conduct screens using hundreds of thousands of single cells in one experiment and continue to scale our technology. With our proprietary guide RNA design algorithm, cloning and manufacturing of lentiviral guide RNA libraries, single-cell library prep and NGS, and bioinformatic analysis, Myllia offers a comprehensive and customized assay development solution. Led by a team of industry experts, including CEO Thomas Moser, CSO Tilmann Buerckstuemmer, and scientific advisor Christoph Bock, Myllia is committed to advancing genetic research and offering groundbreaking solutions.

Join us in exploring the limitless potential of CRISPR technology. Contact us today to learn more and embark on a career at Myllia Biotechnology